Search

Your search keyword '"Lacouture, Mario E."' showing total 14 results
Start Over Author "Lacouture, Mario E." Publication Year Range This year
14 results on '"Lacouture, Mario E."'

1. Oral minoxidil for late alopecia in cancer survivors

Author

Kuo, Alyce Mei-Shiuan, Reingold, Rachel E., Ketosugbo, Kwami F., Pan, Alexander, Kraehenbuehl, Lukas, Dusza, Stephen, Gajria, Devika, Lake, Diana E., Bromberg, Jacqueline F., Traina, Tiffany A., Fornier, Monica N., Gucalp, Ayca, D’Alessandro, Brian M., Rotemberg, Veronica, Dauscher, Megan, Shapiro, Jerry, Goldfarb, Shari B., Markova, Alina, and Lacouture, Mario E.

Published
2024
Full Text
View/download PDF

2. Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique

Author

Gallagher, Emily J., Moore, Heather, Lacouture, Mario E., Dent, Susan F., Farooki, Azeez, Goncalves, Marcus D., Isaacs, Claudine, Johnston, Abigail, Juric, Dejan, Quandt, Zoe, Spring, Laura, Berman, Brian, Decker, Melanie, Hortobagyi, Gabriel N., Kaffenberger, Benjamin H., Kwong, Bernice Y., Pluard, Timothy, Rao, Ruta, Schwartzberg, Lee, and Broder, Michael S.

Published
2024
Full Text
View/download PDF

4. Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)

Author

Zhao, Jimmy L., Antonarakis, Emmanuel S., Cheng, Heather H., George, Daniel J., Aggarwal, Rahul, Riedel, Elyn, Sumiyoshi, Takayuki, Schonhoft, Joseph D., Anderson, Amanda, Mao, Ninghui, Haywood, Samuel, Decker, Brooke, Curley, Tracy, Abida, Wassim, Feng, Felix Y., Knudsen, Karen, Carver, Brett, Lacouture, Mario E., Wyatt, Alexander W., and Rathkopf, Dana

Published
2024
Full Text
View/download PDF

6. Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways

Author

Lacouture, Mario E., primary, Goleva, Elena, additional, Shah, Neil, additional, Rotemberg, Veronica, additional, Kraehenbuehl, Lukas, additional, Ketosugbo, Kwami F., additional, Merghoub, Taha, additional, Maier, Tara, additional, Bang, Alexander, additional, Gu, Stephanie, additional, Salvador, Trina, additional, Moy, Andrea P., additional, Lyubchenko, Taras, additional, Xiao, Olivia, additional, Hall, Clifton F., additional, Berdyshev, Evgeny, additional, Crooks, James, additional, Weight, Ryan, additional, Kern, Jeffrey A., additional, and Leung, Donald Y.M., additional

Published
2024
Full Text
View/download PDF

7. Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy

Author

Friedman, Joshua S., primary, Durham, Benjamin H., additional, Reiner, Anne S., additional, Yabe, Mariko, additional, Petrova‐Drus, Kseniya, additional, Dogan, Ahmet, additional, Pulitzer, Melissa, additional, Busam, Klaus J., additional, Francis, Jasmine H., additional, Rampal, Raajit K., additional, Ulaner, Gary A., additional, Reddy, Ryan, additional, Yeh, Randy, additional, Hatzoglou, Vaios, additional, Lacouture, Mario E., additional, Rotemberg, Veronica, additional, Mazor, Roei D., additional, Hershkovitz‐Rokah, Oshrat, additional, Shpilberg, Ofer, additional, Goyal, Gaurav, additional, Go, Ronald S., additional, Abeykoon, Jithma P., additional, Rech, Karen, additional, Morlote, Diana, additional, Fidai, Shiraz, additional, Gannamani, Vedavyas, additional, Zia, Maryam, additional, Abdel‐Wahab, Omar, additional, Panageas, Katherine S., additional, Rosenblum, Marc K., additional, and Diamond, Eli L., additional

Published
2024
Full Text
View/download PDF

8. Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy

Author

Chen, Steven T, primary, Semenov, Yevgeniy R, additional, Alloo, Allireza, additional, Bach, Daniel Q, additional, Betof Warner, Allison, additional, Bougrine, Amina, additional, Burton, Leeann, additional, Cappelli, Laura C, additional, Castells, Mariana, additional, Cohen, Justine, additional, Dewan, Anna K, additional, Fadden, Riley, additional, Guggina, Lauren, additional, Hegde, Aparna, additional, Huang, Victor, additional, Johnson, Douglas B, additional, Kaffenberger, Benjamin, additional, Kroshinsky, Daniela, additional, Kwatra, Shawn, additional, Kwong, Bernice, additional, Lacouture, Mario E, additional, Larocca, Cecilia, additional, Leventhal, Jonathan, additional, Markova, Alina, additional, McDunn, Jon, additional, Mooradian, Meghan J, additional, Naidoo, Jarushka, additional, Choi, Jennifer, additional, Nambudiri, Vinod, additional, Nelson, Caroline A, additional, Patel, Anisha B, additional, Pimkina, Julia, additional, Rine, Johnathan, additional, Rubin, Krista M, additional, Sauder, Maxwell, additional, Shaigany, Sheila, additional, Shariff, Afreen, additional, Sullivan, Ryan J, additional, Zubiri, Leyre, additional, Reynolds, Kerry L, additional, and LeBoeuf, Nicole R, additional

Published
2024
Full Text
View/download PDF

9. Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways

Author

Lacouture, Mario E; https://orcid.org/0000-0002-4818-3710, Goleva, Elena; https://orcid.org/0000-0002-4685-9318, Shah, Neil; https://orcid.org/0000-0001-5752-6212, Rotemberg, Veronica; https://orcid.org/0000-0003-0639-2677, Kraehenbuehl, Lukas; https://orcid.org/0000-0001-5411-5661, Ketosugbo, Kwami F; https://orcid.org/0000-0003-1637-1941, Merghoub, Taha; https://orcid.org/0000-0002-1518-5111, Maier, Tara; https://orcid.org/0009-0001-7691-404X, Bang, Alexander; https://orcid.org/0000-0002-1700-2411, Gu, Stephanie; https://orcid.org/0000-0002-6416-785X, Salvador, Trina; https://orcid.org/0009-0009-2346-0660, Moy, Andrea P; https://orcid.org/0000-0001-5431-6682, Lyubchenko, Taras; https://orcid.org/0000-0001-9466-5916, Xiao, Olivia; https://orcid.org/0000-0002-3869-5894, Hall, Clifton F; https://orcid.org/0000-0002-5180-1014, Berdyshev, Evgeny; https://orcid.org/0000-0002-1376-0098, Crooks, James; https://orcid.org/0000-0002-0021-5701, Weight, Ryan; https://orcid.org/0009-0006-0982-2096, Kern, Jeffrey A; https://orcid.org/0000-0001-9709-9622, Leung, Donald Y M; https://orcid.org/0000-0002-0177-3844, Lacouture, Mario E; https://orcid.org/0000-0002-4818-3710, Goleva, Elena; https://orcid.org/0000-0002-4685-9318, Shah, Neil; https://orcid.org/0000-0001-5752-6212, Rotemberg, Veronica; https://orcid.org/0000-0003-0639-2677, Kraehenbuehl, Lukas; https://orcid.org/0000-0001-5411-5661, Ketosugbo, Kwami F; https://orcid.org/0000-0003-1637-1941, Merghoub, Taha; https://orcid.org/0000-0002-1518-5111, Maier, Tara; https://orcid.org/0009-0001-7691-404X, Bang, Alexander; https://orcid.org/0000-0002-1700-2411, Gu, Stephanie; https://orcid.org/0000-0002-6416-785X, Salvador, Trina; https://orcid.org/0009-0009-2346-0660, Moy, Andrea P; https://orcid.org/0000-0001-5431-6682, Lyubchenko, Taras; https://orcid.org/0000-0001-9466-5916, Xiao, Olivia; https://orcid.org/0000-0002-3869-5894, Hall, Clifton F; https://orcid.org/0000-0002-5180-1014, Berdyshev, Evgeny; https://orcid.org/0000-0002-1376-0098, Crooks, James; https://orcid.org/0000-0002-0021-5701, Weight, Ryan; https://orcid.org/0009-0006-0982-2096, Kern, Jeffrey A; https://orcid.org/0000-0001-9709-9622, and Leung, Donald Y M; https://orcid.org/0000-0002-0177-3844

Abstract

Purpose: Immune-related cutaneous adverse events (ircAEs) occur in ≥50% of patients treated with checkpoint inhibitors (CPI), but mechanisms are poorly understood. Experimental Design: Phenotyping/biomarker analyses were conducted in 200 patients on CPIs (139 with ircAEs, 61 without, control) to characterize their clinical presentation and immunologic endotypes. Cytokines were evaluated in skin biopsies, skin tape strip (STS) extracts and plasma using real-time PCR and Meso Scale Discovery multiplex cytokine assays. Results: Eight ircAE phenotypes were identified: pruritus (26%), maculopapular rash (MPR; 21%), eczema (19%), lichenoid (11%), urticaria (8%), psoriasiform (6%), vitiligo (5%), and bullous dermatitis (4%). All phenotypes showed skin lymphocyte and eosinophil infiltrates. Skin biopsy PCR revealed the highest increase in IFN-gamma mRNA in patients with lichenoid (p<0.0001) and psoriasiform dermatitis (p<0.01) as compared to patients without ircAEs, while the highest IL-13 mRNA levels were detected in the eczema (p<0.0001, compared to control). IL-17A mRNA was selectively increased in psoriasiform (p<0.001), lichenoid (p<0.0001), bullous dermatitis (p<0.05) and MPR (p<0.001), compared to control. Distinct cytokine profiles were confirmed in STS and plasma. Analysis determined increased skin/plasma IL-4 cytokine in pruritus, skin IL-13 in eczema, plasma IL-5 and IL-31 in eczema and urticaria, and mixed-cytokine pathways in MPR. Broad inhibition via corticosteroids or type 2-cytokine targeted inhibition resulted in clinical benefit in these ircAEs. In contrast, significant skin upregulation of type 1/type 17 pathways was found in psoriasiform, lichenoid, bullous dermatitis, and type 1 activation in vitiligo. Conclusions: Distinct immunologic ircAE endotypes suggest actionable targets for precision medicine-based interventions.

Published
2024

10. Phase 2 Trial of Ruxolitinib Cream for Chronic Cutaneous GvHD

Author

Markova, Alina, primary, Papadopoulos, Esperanza B., additional, Dusza, Stephen, additional, Rotemberg, Veronica, additional, Ostojic, Jelena, additional, Ai, Rizi, additional, Maier, Tara, additional, Lacouture, Mario E., additional, Tamari, Roni, additional, Gyurkocza, Boglarka, additional, Shaffer, Brian C., additional, Scordo, Michael, additional, Perales, Miguel-Angel, additional, Harris, Andrew C., additional, and Ponce, Doris M., additional

Published
2024
Full Text
View/download PDF

13. Skin adverse events of anti-cancer treatments: an examination of drug-adverse events associations.

Author

Salah, Samir, Kerob, Delphine, Pagès, Cècile, Lacouture, Mario E., Sibaud, Vincent, Dousset, Lea, and Khosrotehrani, Kiarash

Subjects
RISK assessment, RADIOTHERAPY, ANTINEOPLASTIC agents, IMMUNOTHERAPY, CONFERENCES & conventions, CANCER chemotherapy, TUMORS, DRUG eruptions, DISEASE risk factors
Abstract

Introduction/Objectives Although anti-cancer treatments, including chemotherapy (CTs), targeted therapies (TTs), radiation therapy, and immunotherapy (ITs), effectively treat cancer, they can cause significant skinrelated toxicities (AEs). These toxicities can lead to discomfort and therapy discontinuation. This study investigated these associations using a large dataset. Materials/Methods The study utilised the US FDA Adverse Reporting System (FAERS) dataset, focusing on Healthcare Professional reports between January 2013 -- September 2022, encompassing 3,399,830 reports, 3084 drugs, and 16,347 AEs. To minimise false positives, we employed a nearest-neighbour matching model on demographics and severity criteria and addressed the inflation of error rates due to the multiplicity of tests. Results We identified 146 marketed anti-cancer drugs in the database with at least five reports of skin AEs. Of the 2757 drug-AE pairs, 708 displayed a significant reporting odds ratio (ROR) >1, involving 102 drugs and 135 skin AEs. Rash was significantly associated with 44 drugs and dry skin with 25 drugs. Methotrexate was significantly associated with 35 different AEs and anti-BRAF vemurafenib with 26 AEs. TTs were present in 57% of the pairs, CTs in 38%, and immune checkpoint blocking agents in 5%. Multikinase inhibitors were present in 15% of the pairs, followed by antimetabolites (14%). Conclusion This study used a large dataset to examine associations between cancer drugs and skin AEs. 146 anti-cancer drugs were found to have skin AEs, with rash and dry skin being the most reported AEs. TTs were most associated with skin AEs, followed by CTs. Methotrexate and vemurafenib had the most significant number of associations. These data don't allow evaluation of skin AE incidence with anti-cancer drugs as they are probably under-reported, but the findings do emphasise the importance of monitoring skin AEs in patients exposed to anti-cancer treatments. [ABSTRACT FROM AUTHOR]

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results